After Pfizer and Serum Institute of India, now Hyderabad-based Bharat Biotech has applied for emergency use authorisation for their investigational vaccine candidate Covaxin to the Indian regulator on Monday.
The company is conducting a 26,000 subjects phase 3 efficacy trial in India to determine the efficacy of its candidate. This is one of the largest efficacy trials conducted in the country. The company has Phase 1 and phase 2 data ready and would submit the interim data from large scale efficacy trials to the Drug Controller General of India (DCGI) for review.
Officials from the Central Drugs Standard Control Organization (CDSCO), the Indian Council of Medical Research (ICMR) have been in regular touch with BBIL along with the expert committee on vaccine administration.
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
First Published: Mon, December 07 2020. 21:57 IST